TCR-T cell therapy enhances the specific recognition and affinity of T lymphocytes for tumor cells by transfecting common T cells with chimeric antigen receptors or TCRa/β heterodimers. It can effectively identify and kill tumor cells, and has a significant advantage in the treatment of solid tumors. In recent years, with support from national policies, in-depth research on therapy technology, and the discovery of new HERV-E targets, TCR-T cell therapy has begun to enter the market for renal cell carcinoma drugs. For this reason, based on research into this market, Frost & Sullivan (Frost & Sullivan) has released a relevant industry report.
